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Urothelial organoids originating from Cd49fhigh
mouse stem cells display Notch-dependent
differentiation capacity
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Understanding urothelial stem cell biology and differentiation has been limited by the lack of
methods for their unlimited propagation. Here, we establish mouse urothelial organoids that
can be maintained uninterruptedly for >1 year. Organoid growth is dependent on EGF and
Wnt activators. High CD49f/ITGA6 expression features a subpopulation of organoid-forming
cells expressing basal markers. Upon differentiation, multilayered organoids undergo reduced
proliferation, decreased cell layer number, urothelial program activation, and acquisition of
barrier function. Pharmacological modulation of PPARγ and EGFR promotes differentiation.
RNA sequencing highlighted genesets enriched in proliferative organoids (i.e. ribosome) and
transcriptional networks involved in differentiation, including expression of Wnt ligands and
Notch components. Single-cell RNA sequencing (scRNA-Seq) analysis of the organoids
revealed five clusters with distinct gene expression profiles. Together with the use of γ-
secretase inhibitors, scRNA-Seq confirms that Notch signaling is required for differentiation.
Urothelial organoids provide a powerful tool to study cell regeneration and differentiation.
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Urinary bladder diseases, most notably cystitis and bladdercancer, are important medical problems that generatehigh costs to the health systems worldwide. The bladder,
ureters, renal pelvis, and part of the urethra are lined by a mul-
tilayered epithelium with some features reminiscent of the skin
epidermis. The urothelium consists of three cell types (basal,
intermediate, and umbrella) organized in 3–7 layers, with con-
siderable species-related variation (Fig. 1a). In the mouse, basal
cells are small, cuboidal, and express CD44 and KRT5; a fraction
thereof express KRT14 and have stem cell properties1. Inter-
mediate cells are larger, express KRT5, KRT8, KRT18, and uro-
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largest, multinucleated, highly specialized cells expressing high
levels of uroplakins and KRT202–4. Umbrella cells constitute the
physiological barrier to the passage of water, electrolytes, and urea
through tight junctions, responsible for the high resistance
paracellular pathway5; a role for other urothelial cell types in
barrier function has not been demonstrated6. Unlike the skin
epidermis, the urothelium has a very slow turnover7 yet it pre-
serves a robust capacity to restore epithelial integrity upon
damage1,8.
Several key transcription factor networks involved in urothelial
proliferation/differentiation have been identified using 2D cul-
tures and genetic mouse models. PPARγ is expressed in the
urothelium throughout embryonic development and in the adult9
and it has been shown to participate in proliferation and differ-
entiation, cooperating with FOXA1, KLF5, and EGFR signal-
ing10–12. The Southgate laboratory has shown that EGFR
inhibition can potentiate the activity of PPARγ agonists and up-
regulate the expression of urothelial differentiation markers13,14.
Retinoic acid signaling also plays an important role in the dif-
ferentiation of urothelial cells during development and in tissue
regeneration upon damage in the adult bladder15. However, the
role of these pathways in urothelial differentiation is incompletely
understood, in part due to the lack of methods to continually
propagate normal cells, and improved cellular models are criti-
cally required.
In recent years, three-dimensional (3D) organoids have
become a powerful tool to study the molecular and cellular basis
of epithelial differentiation, allowing consistent culture and per-
petuation16. Organoids are derived from cells capable of self-
renewal and self-organization through cell sorting and lineage
commitment in an in vivo-like manner17. The Clevers laboratory
has pioneered the establishment of organoids from a wide variety
of epithelia, including mouse small intestine16, liver18, prostate19,
and pancreas20. Organoids facilitate studying tissue biology,
modeling disease, drug screening, and establishing a solid basis
for regenerative medicine and gene therapy21. The majority of
published studies have focused on organoids derived from simple
epithelia. Recently, Lee et al.22 have reported the establishment of
organoids from human bladder tumors and Mullenders et al.23
have described the features of normal mouse basal organoids and
human bladder organoids. However, these reports have not
explored in depth the potential of urothelial organoids to
understand urothelial biology.
Here, we establish and characterize healthy tissue-derived
mouse urothelial organoids and show that high CD49f (integrin
α6, ITGA6) expression (CD49fhigh) characterizes a urothelial cell
population containing stem cells able to self-perpetuate as orga-
noids. We define their requirements for growth and differentia-
tion and demonstrate their functional properties including barrier
formation. Using bulk transcriptomics we identify a role for the
Notch pathway in urothelial differentiation. scRNA-Seq allowed
us to unveil gene expression signatures featuring Basal, Basal-
Proliferative, Intermediate, and Luminal urothelial cells. This
analysis further supports that expression of Notch target genes is
transiently activated during urothelial differentiation. The orga-
noids described should facilitate and accelerate the study of the
molecular pathophysiology of bladder diseases, including the
interaction of epithelial cells with pathogens and the mechanisms
involved in malignant transformation of the urothelium.
Results
Urothelial organoids can be established and perpetuated. To
establish organoids, we isolated cells from digests of urothelial
scrapings. This unselected cell population allowed establishing
urothelial organoids that could be consistently passaged. To
characterize the cell populations present therein, we used flow
cytometry analysis with specific antibodies detecting leukocytes
(CD45), fibroblasts (CD140a), endothelial cells (CD31), and
erythrocytes (Ter119); approximately 20% of single cells lacked
these markers. The majority of the cells lacking these markers
were EpCAM+ (>60%), indicating their epithelial nature (Sup-
plementary Fig. 1a).
Unselected cells from urothelial digests, or EpCAM+ cells
sorted from them, cultured in Matrigel with complete medium
(including EGF, LY2157299, Noggin, WNT3A, RSPO1)21,24 led
to growth of multilayered organoids over 1 week. Under these
conditions, lumen-containing organoids were very rare (Fig. 1b,
Supplementary Fig. 1b). Organoids could be consistently passaged
and maintained in culture uninterruptedly for >1 year with stable
morphology but a tendency for organoids to become enriched in
cells with basal features over time was noted (Supplementary
Fig. 1b–d). Unless otherwise indicated, the experiments reported
used unsorted urothelial cells and >2 independent organoid
cultures at passage <10.
To identify critical growth factors required for organoid
formation, we performed leave-one-out experiments where we
removed each complete medium component individually or in
combination. At day 7, we observed a statistically significant
reduction of organoid number upon omission of EGF, WNT3A,
RSPO1, or WNT3A+ RSPO1 (Fig. 1b, c). As reported for other
tissues, Noggin was not required to establish organoids but it was
essential for long-term perpetuation25. Despite their high
proliferative potential, organoids did not form tumors upon
xenotransplantation under the skin (Supplementary Fig. 1e) or in
the kidney capsule.
CD49fhigh defines cells with organoid-forming capacity. To
define the cell type of origin of the organoids, we isolated uro-
thelial cell subpopulations based on marker expression and size.
Fig. 1 CD49f labels an organoid-forming urothelial cell population with stem cell features. a Urothelial cyto-organization highlighting the three cell layers:
basal (CD49f and KRT5), intermediate (KRT5), and luminal (WGA-binding) markers. U, urothelium; LP, lamina propria (scale bar, 50 μm). Color code for
the scheme: brown, basal; pink, basal-proliferative; blue, intermediate; green, umbrella. b Representative images of organoids from low-passage urothelial
cell suspensions embedded in Matrigel in complete medium (upper left). The remaining panels correspond to the leave-one-out experiments (see panel c)
(scale bar, 500 μm). c Quantification of organoid growth in leave-one-out experiments (WR condition: WNT3A and RSPO1 were omitted). Number of
organoids normalized to complete medium; error bars indicate SEM. d, e FACS plots depicting the analysis and isolation of fresh epithelial cells according to
cell surface markers (EpCAM, CD49f, CD44, and WGA) and size (n= 2) (scale bar, 500 μm). f Quantification of the organoid-forming capacity of freshly
isolated and sorted urothelial cells (100 cells/Matrigel drop) compared to the unsorted population (Urothelium); results from a representative experiment
(n= 2); error bars indicate SEM. g Clonal growth capacity of freshly isolated urothelial cells FACS-sorted according to CD49f expression (CD49fhigh vs.
CD49flow) and seeded at 1, 10, and 100 cells/Matrigel drop (n= 3). The proportion of Matrigel drops showing outgrowth (bars, Y-axis) and the number of
organoids/drop (1, 2, 3, and 4; according to the color code) are shown. h Monoclonal origin of organoids established starting from a 1:1 mixture of EGFP-
and mTomato-expressing cells (n= 2) (scale bar, 500 μm). ANOVA and Mann–Whitney tests were applied; *p≤ 0.05, **p≤ 0.01; ***p≤ 0.001. Source
data are provided as a Source Data file
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CD49f expression identifies a cancer cell population with basal
features26, suggesting that it might serve as a stem cell marker.
Immunofluorescence analysis of normal mouse bladder showed
that CD49f is expressed both in the epithelium and in the lamina
propria; in the urothelium, CD49f selectively labels basal cells
(Fig. 1a)27. Compared to CD49flow cells, FACS-purified
CD49fhigh cells were enriched in basal markers whereas
CD49flow cells were enriched in luminal markers (Supplementary
Fig. 1f). Lectins have also been used effectively as cell-type specific
markers. Therefore, we screened a panel of lectins and found that
the cytoplasm and plasma membrane of umbrella cells is strongly
labeled by wheat germ agglutinin (WGA), while the remaining
urothelial cells are weakly labeled (Fig. 1a). FACS-sorting of
freshly isolated urothelial EpCAM+ cells on the basis of Cd49f,
WGA-binding, and cell size—which augments towards the lumen
—showed that CD49fhigh/WGA+ cells (basal) have the highest
organoid-forming capacity. By contrast, CD49flow cells (inter-
mediate and luminal) were essentially unable to form organoids,
regardless of WGA labeling or size (small vs. large) (Fig. 1d).
CD44 has also been proposed as an urothelial stem/basal cell
marker3,28: most CD44+ cells were CD49f+ and both CD49fhigh/
CD44high and CD49fhigh/CD44low cells were able to form orga-
noids displaying a similar phenotype (Fig. 1e, Supplementary
Fig. 1g, h). However, the number of organoids was highest in the
CD49fhigh/CD44high population (P= 0.029) (Fig. 1f). Low-
density seeding of freshly isolated urothelial cells (1–100 cells/
drop) showed that CD49fhigh cells have a markedly increased
clonal growth capacity and that organoids can be established
from single cells only from this cell population (Fig. 1g). GFP-
and Tomato-labeled sorted cells derived from organoids were
mixed prior to seeding in Matrigel at 1:1 ratios and only single-
colored organoids were identified, supporting the notion that
organoids are monoclonal in origin (Fig. 1h). Altogether, these
results indicate that CD49fhigh and CD44high label the urothelial
cell population with highest organoid-forming potential.
Organoids recapitulate urothelial differentiation and function.
To induce differentiation, organoids that had been maintained for
7 days in proliferation conditions (P) were cultured in medium
without EGF, LY2157299, Noggin, WNT3A, and RSPO1 (dif-
ferentiation medium, D) for an additional 7 days: a dramatic
morphological change was observed, including an increase in
diameter and organoid lumen formation, and reduced cell layer
thickness (Fig. 2a–d). In proliferation conditions, organoids
expressed high levels of Ccne1 transcripts and Ki67 and resemble
basal cells expressing Cd49f, Cd44, Tp63, Krt14, and Krt5 and low
levels of uroplakins (Fig. 2e–g). By contrast, upon differentiation,
organoids showed marked downregulation of cell cycle mRNAs
and proteins, a modestly decreased expression of basal markers,
and upregulation of mRNA expression of Foxa1 and Pparγ,
intermediate cell markers (Krt8 and Krt18), uroplakins (Upk2 and
Upk3a), and Krt20 (Fig. 2e–g). The corresponding proteins dis-
played the canonical distribution observed in the urothelium:
TP63 and CD49f were found in the outer layer of proliferative
organoids while PPARγ and UPK3a displayed heterogenous
expression in cells lining the lumen of differentiated organoids
(Fig. 2f, g). Expression of KRT14 and KRT5 persisted in differ-
entiated organoids, possibly reflecting the half-life of these pro-
teins and the slow differentiation dynamics of urothelial cells in
tissues. KRT20 was generally undetectable at the protein level, as
were multinucleated umbrella cells.
Functional competence of organoids was assessed using
urothelial barrier assays based on paracellular diffusion of
FITC-labeled low molecular weight dextran (FITC-dextran) and
fluorescence recovery after photobleaching (FRAP) (Fig. 3a–d).
Urothelial organoids were cultured with medium containing
FITC-dextran during both proliferation and differentiation stages.
Prior to photobleaching, the lumen of D organoids showed a
significantly higher normalized FITC intensity than the lumen of
P organoids, suggesting epithelial layer tightness (Fig. 3b, c). After
photobleaching, and during a recovery period of up to 14 h,
differentiated organoids proved to be impermeable to FITC-
dextran whereas proliferative cultures were heterogeneous and
contained a mixture of impermeable and permeable organoids
(Fig. 3b, d, Supplementary Movie 1). The differences in barrier
function acquisition were statistically significant and increased
over time of recovery. These findings confirm the ability of
organoids to acquire features of differentiated urothelium.
PPARγ activation and EGFR inhibition enhance differentia-
tion. We used the PPARγ agonist Roziglitazone (Rz) and the
EGFR inhibitor Erlotinib to determine if they could further
induce urothelial differentiation. P organoids cultured for an
additional 7 days in the presence of Rz+ Erlotinib acquired larger
lumina and showed significantly lower Ki67 labeling, when
compared to untreated samples (Fig. 4a, b). Cd49f and Cd44
mRNAs were down-regulated while uroplakin transcripts and
proteins were up-regulated (Fig. 4a–c). In D organoids, Rz or
Erlotinib alone caused reduced expression of Cd49f and Cd44
mRNAs (Supplementary Fig. 2a). When combined, they led to
highest Foxa1 and uroplakin mRNA expression and to a sig-
nificant reduction of lumen formation. UPK expression and
lumen formation were often, but not always, correlated. There
were no major changes in Ki67 and cleaved-caspase-3 labeling
upon culture of differentiated organoids with Rz+ Erlotinib
(Fig. 4a, b). Treatment of organoids with the PPARγ inverse
agonist T0070907 at the initiation of the differentiation protocol
had minor effects on lumen formation, Ki67, and UPK3a
expression (Fig. 4a–c, Supplementary Fig. 2b, c), suggesting that
pathways other than PPARγ activation contribute to differentia-
tion. KRT20 was not detected in any of the conditions analyzed.
These results indicate that PPARγ activation, together with EGFR
inhibition, effectively promote urothelial organoid differentiation.
Cells in differentiated organoids can re-enter the cell cycle. To
determine whether cells could re-enter the cell cycle after indu-
cing differentiation, organoids cultured in differentiation med-
ium, or in differentiation medium supplemented with Rz and
Erlotinib, were maintained for an additional 7 days in complete
medium (Fig. 5a–c, Supplementary Fig. 3). In both cases, differ-
entiated organoids (D➔P and D+ Rz+ Erlo➔P, Fig. 5a)
acquired a multilayer organization similar to that of proliferative
organoids and basal cells showed uniform expression of KI67 and
TP63 (Fig. 5c). However, the differences in marker gene expres-
sion at the mRNA level were modest, possibly due to pre-existing
transcripts (Fig. 5b). The wide re-expression of KI67 in the basal
cell layer strongly suggests that incompletely differentiated uro-
thelial cells re-enter the cell cycle rather an overgrowth of a low-
frequency stem cell population (Fig. 5c). Accordingly, 88.9% of
cells in differentiated organoids were CD49fhigh (Supplementary
Fig. 3c). Organoids maintained in differentiation medium (D➔D)
showed highest mRNA expression of Foxa1, Pparγ, and uropla-
kins; however, smaller lumina and higher cell death were noted
(Supplementary Fig. 3b, c). These results indicate that organoids
acquire a cyto-organization and differentiation characteristic of
the urothelium and retain proliferative potential.
Transcriptome analysis unveils urothelial differentiation
pathways. To interrogate the transcriptomic programs governing
organoid differentiation we performed RNAseq of three
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independent paired P and D organoid cultures (Supplementary
Fig. 4a). Principal component analysis (PCA) showed that pro-
liferative organoids clustered closely whereas their differentiated
counterparts showed greater transcriptome divergence (Supple-
mentary Fig. 4b); 4100 genes were differentially expressed (FDR
< 0.05; Supplementary Data 1). Among the top upregulated
transcripts in P conditions were those involved in cell cycle (i.e.
Cdk1, Aurkb, Ccnb2, and Ki67), inhibition of apoptosis (Birc5),
epidermal differentiation (i.e. Sprr2f, Crnn, Stfa3), cytoskeletal
regulation (Kif15, Kif4), and stemness (Cd34). By contrast, tran-
scripts significantly up-regulated upon differentiation included
those involved in urothelial cell functions (i.e. Upk1a, Upk2,
Upk3a), glycosylation (i.e. Wbscr17, Ugt2b34, Galnt14), and TGF-
β signaling (i.e. Fstl1, Ltbp1, Fstl4) (Supplementary Data 1). Of
note, several genes involved in xenobiotic metabolism (i.e. Cyp2f2,
Adh7, Gstm1) are among those differentially expressed, under-
scoring the relevance of this pathway to bladder carcinogenesis29.
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urothelial markers (i.e. Krt14, Krt5, Cd44, Cd49f, and Trp63) and
the upregulation of suprabasal markers (i.e. Krt19, Krt8, Foxa1,
Pparγ, Upk1a, Upk1b, Upk2, and Upk3a) in D conditions (Fig. 6a,
Supplementary Fig. 4c), as well as the robust regulation of addi-
tional keratin species (Supplementary Fig. 4d).
Manual curation also revealed dynamic changes in expression
of cell–cell adhesion genes. Transcripts coding for tight junction
components showed two distinct expression patterns: Cldn1,
Cldn8, Cldn12, and Cldn25 were down-regulated upon differ-
entiation whereas Cldn3, Cldn4, Cldn7, Cldn23, Ocln, Zo-1, Zo-2,
and Zo-3 were up-regulated (Fig. 6b), suggesting distinct
functions and cellular distribution for the corresponding proteins.
Selected mRNA expression changes were confirmed in indepen-
dent organoid samples and in normal urothelium
(Supplementary Fig. 4e, f). Apical expression of ZO-1 and
CLDN4 was confirmed in differentiated organoids (Fig. 6c). The
predicted expression pattern of CLDN1, CLDN3, and CLDN4
was validated using information from the Human Protein Atlas
(https://www.proteinatlas.org/). Epithelial impermeability and
endocytic traffic were significantly up-regulated in D organoids,
in agreement with results of the FITC-dextran assays
described above.
Gene set enrichment analysis (GSEA) revealed a highly
significant downregulation of the activity of pathways involved
in cell cycle, DNA repair, RNA biology, protein synthesis, and
cytokines in D organoids; this was accompanied by increased
activity of pathways involved in epithelial differentiation/cell–cell
adhesion, intracellular traffic (endocytosis, lysosome), and
Fig. 2 Growth factor-depleted organoids recapitulate the urothelial differentiation program. a Experimental design applied to induce urothelial organoid
differentiation: organoids cultured until day 7 in complete medium were maintained for seven additional days in differentiation medium. b Image of
organoids displaying the features quantified in panel c: d, diameter; l, lumen; t, thickness of the epithelial layer. The signal distribution was measured across
the organoids as indicated by the arrow in both cases (scale bar, 100 μm). c Signal distribution (in microns) acquired by confocal microscopy displaying the
quantification of organoid features (diameter) of individual proliferative (P) (n= 57) and differentiated (D) (n= 71) organoids; color code indicates the
intensity of the signal: green, low; yellow, intermediate; red, high. d Violin plots representing organoid features. e RT–qPCR analysis of expression of genes
regulated during differentiation. Data are normalized to Hprt expression (Mann–Whitney test, error bars indicate SD). f Western blot (WB) analysis
showing expression of TP63 (basal marker), UPK3a, and UPK1b (luminal markers) in P and D organoids in three independent experiments. Urothelial
bladder cancer cell lines (ScaBER, RT112, VMCUB1, and RT4) were used as controls. g Immunofluorescence analysis of urothelial markers in P and D








































































Fig. 3 Organoids cultured in differentiated conditions are functionally competent and acquire barrier function. a Experimental design to assess barrier
function in organoid cultures using FITC-dextran and fluorescence recovery after photobleaching (FRAP). b Example of P and D organoids during the FRAP
assay (pre-bleaching, post-bleaching and recovery—3.5 and 14 h) (scale bar, 1000 μm). c Quantification of FITC-dextran intensity of P (n= 5) and D (n=
7) organoids in the pre-bleaching phase showing specific FITC-dextran retention in differentiated organoids (Mann–Whitney test, error bars indicate SD).
d Fluorescence recovery in P (n= 5) (left) and D (n= 7) organoids (middle); mean fluorescence recovery in P vs D organoids (Mann–Whitney test, error
bars indicate SD). *p≤ 0.05, **p≤ 0.01. Source data are provided as a Source Data file
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Fig. 4 Pharmacological modulation of EGFR and PPARγ activity potentiates organoid differentiation. a Representative phase contrast and
immunofluorescence images of proliferative (P) and differentiated (D) organoids cultured in the presence of drugs modulating PPARγ (Roziglitazone, Rz)
or EGFR activity (Erlotinib, Erlo) (scale bars: brightfield, 500 μm; immunofluorescence, 250 μm). b Quantification of lumen formation (Mann–Whitney
test), Ki67, UPK3a, and cleaved-caspase-3 expression (Bonferroni test) in organoids cultured as described in panel a. c Heatmap representing RT–qPCR
expression analysis of cell cycle and canonical urothelial differentiation markers in P or D organoids treated with Rz+ Erlotinib, and with the PPARγ inverse
agonist T0070907 (n= 2). *p≤ 0.05, **p≤ 0.01; ***p≤ 0.001. Source data are provided as a Source Data file
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Fig. 5 Differentiated organoids are able to re-enter the cell cycle upon exposure to complete medium. a Experimental strategy: day 7 P organoids were
maintained for 7 additional days either in complete medium (P), differentiation medium (D), or differentiation medium supplemented with Roziglitazone
and Erlotinib (D+ Rz+ Erlo). D organoids were then switched to complete medium (D−P; D+ Rz+ Erlo−P) for 7 additional days. b RT–qPCR analysis of
expression of genes regulated during differentiation. Data are normalized to Hprt expression (n= 1 biological replicate). c Representative phase contrast
images of organoid cultures (scale bar, 500 μm), H&E staining, and immunohistochemistry for Ki67, TP63, and UPK3a (n= 1 biological replicate) (scale
bar, 250 μm). Source data are provided as a Source Data file
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Fig. 6 Transcriptome analysis reveals organoid differentiation and identifies pathways involved therein. a Heatmap showing the expression (FPKM,
RNAseq) of key urothelial differentiation genes in P and D organoids (n= 3/group; paired samples). b Heatmap showing the expression of genes related to
tight junctions (claudins and tight junction/Zo proteins) (FPKM) in P and D organoids (n= 3/group). c Immunofluorescence analysis of the expression of
ZO-1 and KRT5; immunohistochemical analysis of CLDN4 in the same samples; L (Lumen) (scale bar, 250 μm). d Enrichment plots showing the
upregulation of ribosome pathway genes and the downregulation of tight junction component genes in P organoids. e ISMARA analysis of top transcription
factor motifs (ranked by z-scores) significantly enriched in the promoters of genes differentially expressed in P vs. D organoids; for the z-score of motifs
enriched in D organoids. Source data are provided as a Source Data file
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signaling (phosphatidylinositol, Notch, Wnt, MAPK, mTOR)
(Table 1).
Promoter motif analysis of differentially expressed genes using
ISMARA revealed significant enrichment in motifs of TF involved
in proliferation (E2F, MYC, MYB) and hypoxia regulation
(HIF1A) in proliferative conditions. By contrast, the genes
differentially expressed upon differentiation showed enrichment
of motifs corresponding to chromatin regulators (CHD1, EZH2,
IKZF1), Hippo pathway (TEAD3, TEAD4), and
epithelial–mesenchymal transition regulators (SNAI1, ZEB1,
ZEB2) (Fig. 6d), pointing to transcriptional networks regulating
cell differentiation in the urothelium.
Wnt and Notch signaling in organoid differentiation. The
pathway analyses suggested roles of the Wnt and Notch pathways
in urothelial differentiation. Therefore, we analyzed the effects of
drugs targeting both pathways.
The GSK3β inhibitor CHIR99021—acting as a Wnt agonist—
had no major effect on organoid morphology when added to
proliferative organoids for 7 days. CHIR99021 induced an
increase in mRNA expression of the Wnt target genes Mmp7
and Axin2, as well as proliferation markers (Ccne1 and Pcna),
consistent with the growth promoting effect of Wnt activation
(Supplementary Fig. 5a–c). There were no significant changes in
the expression of basal or urothelial markers. Differentiating
organoids treated with CHIR99021 displayed a more solid aspect
and a significant reduction of lumen formation. There was a
similar up-regulated expression of Mmp7 and Axin2, associated
with reduced expression of urothelial markers (Supplementary
Fig. 5a–c). To assess the role of endogenous Wnt ligands, we
analyzed the effect of the porcupine inhibitor IWP-2 on
differentiating organoids: a significant reduction of lumen
formation, expression of Wnt target genes, and Ccne1 mRNA
was observed. A modest upregulation of CD49f and CD44
transcripts—without major effects on the expression of urothelial
differentiation markers—was detected (Supplementary Fig. 5d–f).
Altogether, these data support the notion that the Wnt pathway
participates in the maintenance of a progenitor, less differen-
tiated, phenotype.
Regarding Notch, the γ-secretase inhibitor DBZ significantly
reduced the expression of the Notch target HES1 at the mRNA
and protein levels and completely abrogated lumen formation in
differentiating organoids (Fig. 7a–c, e). In these conditions, Notch
inhibition resulted in a modest increase in the mRNA expression
of basal markers, an upregulation of TP63, and a significantly
reduced expression of luminal markers (Upk1b, Upk2, Upk3a, and
Krt20 mRNAs, and UPK1b) (Fig. 7c–f). Similar results were
obtained with DAPT, a different γ-secretase inhibitor (Supple-
mentary Fig. 6). Cd49fhigh cells from DAPT-treated differentiated
organoids showed increased organoid formation capacity.
Altogether, these data support the notion that Notch signaling
participates in urothelial differentiation.
Single-cell organoid RNA-Seq unveils distinct cell populations.
To analyze differentiation programs in the organoids with higher
resolution, we performed scRNA-Seq (P organoids, n= 6826
cells; D organoids, n= 4896 cells). Dimensionality reduction and
unsupervised clustering revealed four and three communities in P
and D organoids, respectively (Fig. 8a). Detailed results of the
analyses are provided in Supplementary Data 2. In proliferative
conditions, the clusters displayed features characteristic of Basal-
Proliferative, Basal, Intermediate-Low, and Intermediate-High
cells. In differentiated conditions, Basal, Intermediate, and
Luminal clusters were identified. The Basal-Proliferative cluster
was only found in organoids maintained in complete medium
whereas the Luminal cluster was exclusive to the differentiated
organoids (Fig. 8a, b). The two Basal clusters identified in pro-
liferation conditions shared expression of Krt14, Trp63, Itga6/
Cd49f, and Itgb4 whereas the Basal-Proliferative was selectively
enriched in cell cycle genes (Fig. 8c, Supplementary Data 2). The
Intermediate-Low cluster was characterized by expression of basal
and intermediate (i.e. Krt8) markers, transcripts of tight junction
components (Tjp1, Cldn4, Cldn7), and known (Klf5) as well as
candidate (Foxq1) urothelial transcription factors. The
Intermediate-High cluster showed increased expression of genes
up-regulated in the Intermediate-Low cluster and of Psca, iden-
tified in this study as a marker of urothelial differentiation
(Fig. 8c). The genesets enriched in the Basal and Intermediate
clusters were similar in proliferative and differentiated organoids.
The Luminal cluster showed higher levels of expression of
Intermediate cluster markers as well as of uroplakins (Fig. 8c).
Among the differentially expressed genes (DEGs) in the Basal
clusters were those coding for several Wnt ligands (Wls, Wnt10a,
Wnt4, and Wnt5a) (Fig. 8d). Importantly, components of the
Notch pathway were also differentially expressed: Notch1 was
enriched in Basal clusters whereas Jag1 and Hes1 were enriched in
the Intermediate-Low and Intermediate clusters (P and D
organoids, respectively) (Fig. 8d). These results suggest that the
Notch pathway is transiently activated during urothelial
differentiation.
An integrated analysis of both organoid scRNA-Seq datasets
yielded five clusters with differentially expressed genes featuring
Basal, Basal-Proliferative, Intermediate, Intermediate-High, and
Table 1 GSEA showing the top 25 pathways (Kyoto
Encyclopedia of Genes) significantly enriched in
proliferative and differentiated organoids*
Proliferative organoids Differentiated organoids
Ribosome Lysosome
DNA replication Endocytosis
Cell cycle Focal adhesion
Parkinsons disease Neuroactive ligand receptor
interaction




Pyrimidine metabolism Pathways in cancer
Alzheimers disease Tight Junction
Purine metabolim B cell receptor signaling
Base excision repair Axon guidance
Mismatch repair Inositol phosphate metabolism
Oocyte meiosis Other glycan degradation
Nucleotide excision repair Leukocyte transendothelial
migration
Homologous recombination Notch signaling pathway
RNA polymerase Fcγ R-mediated phagocytosis
RNA degradation Endometrial cancer
Systemic lupos erythematosus Neurotrophin signaling pathway
Proteasome Wnt signaling pathway
N-glycan biosynthesis Mapk signaling pathway
Protein export Apoptosis
Amino sugar and nucleotide sugar
metabolism
Adherens Junction




Cardiac muscle contraction mTOR signaling pathway
aAll pathways significant with FDR q-value <0.05
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Luminal cells (Fig. 8e, Supplementary Fig. 7c). The DEGs
characteristic of each cluster highly overlap with the ones of the
individual analysis (Supplementary Fig. 8) suggesting a robust
clusterization. Indeed, the Basal and a single Intermediate cluster
are largely shared by both organoid populations. The Basal-
Proliferative and Luminal clusters were consistently preserved in
the integrated analysis (Fig. 8e). Supplementary Fig. 9 shows the
expression of selected cell layer markers. Altogether, these
findings indicate that the transcriptomes of organoids in
proliferation and differentiation conditions share similarities
(Basal, Intermediate clusters) but also display unique features
(Basal-Proliferative or Luminal clusters).
b
c














































































































































Fig. 7 Notch pathway inhibition prevents the differentiation of urothelial organoids. a Phase contrast images of D organoids cultured in the presence of the
γ-secretase inhibition (n= 4) (scale bar, 500 μm). b Quantification of the effects of DBZ on lumen formation (Mann–Whitney test). c Western blot
analysis showing the expression of TP63 (basal marker), UPK3a, and UPK1b (luminal markers). d H&E and HES1 expression in organoids treated with DBZ
(scale bar, 250 μm). e RT–qPCR analysis of expression of Notch target genes, proliferation, and urothelial differentiation markers in D organoids treated
with DBZ; results were normalized to Hprt expression. f Immunofluorescence highlighting TP63 upregulation and UPK3a donwregulation upon treatment
with DBZ (scale bar, 250 μm). ***p≤ 0.001. Source data are provided as a Source Data file
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Fig. 8 Single-cell RNAseq reveals distinct cell populations within P and D organoids. a Transcriptomic clusters in P (n= 6826 cells) and D (n= 4896 cells)
organoids visualized using uniform manifold approximation and projection (uMAP) plots, colored according to cluster. b Proportion of cells from P and D
organoids contributing to each of the clusters shown in panel a. c Heatmap depicting expression of selected cluster markers identified by differential
expression analysis (Wilcoxon rank-sum test). d Dot plot depicting the expression of significantly differentially expressed genes from the Wnt and Notch
signaling pathways in P and D organoids, according to cell clusters. e UMAP plots visualizing integrated analysis of cells from P and D organoids as a joint
plot (left, n= 11722) or separate plots (P, center; D, right). For P organoids: B (Basal), BP (Basal-Proliferative), IL (Intermediate-Low) and IH (Intermediate-
High); for D organoids: B (Basal), I (Intermediate), and L (Luminal). Source data are provided as a Source Data file
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Discussion
The establishment of conditions for the self-renewal and differ-
entiation of urothelial stem cells and the identification of markers
thereof are crucial for an improved understanding of homeostasis
and dysregulation in disease. In this work, we show that the
Cd49fhigh basal urothelial population contains a subset of cells
with stem cell properties and long-term growth potential. Upon
depletion of growth factors, these cells largely recapitulate uro-
thelial differentiation, allowing to uncover pathways involved
therein and providing an important resource for cell biology
studies and approaches to regenerative and cancer medicine.
Cd49f/α6 integrin labels a population of urothelial basal cells
that is reminiscent of the α2β1 and α3β1 integrin-expressing basal
skin epidermal stem cells30, underscoring that similar hierarchies
exist in stratified epithelia despite fundamental differences in
proliferation dynamics. The integrated scRNA-Seq analysis
revealed that β4 integrin is also significantly up-regulated in the
Basal cell cluster (Supplementary Fig. 9). The population of
Cd49fhigh cells is heterogeneous and it will be important to
identify subsets with highest self-renewal potential.
The growth factor dependencies of Cd49fhigh cells and the
growth pathways involved in bladder cancer reveals striking
parallelisms. Cd49f and Cd44, highly expressed in proliferative
cells with highest organoid-forming capacity, have been proposed
as markers of the aggressive basal/squamous-like (BASQ) bladder
cancer subtype27,31,32. The urothelial organoids reported here
display a predominant basal phenotype and are critically
dependent on EGF for growth. Similarly, BASQ-type bladder
tumors show EGFR pathway deregulation, mainly through EGFR
amplification, and are highly sensitive to EGFR inhibitors both
in vitro and in xenograft models33. Wnt ligands are also required
for optimal urothelial organoid growth, consistent with in vivo
data indicating that stromal Wnt induced by epithelial Shh is
required for urothelial recovery from damage impinged by
infection or chemical injury34. Addition of the GSK3β inhibitor,
acting as a Wnt agonist35, to organoids prevented the upregula-
tion of urothelial markers in differentiation conditions. scRNA-
Seq analysis showed that Wnt ligand mRNAs are selectively up-
regulated in cells with basal features and Wnt pathway inhibition
reduced the number of lumen-containing organoids, suggesting
that epithelial-autonomous Wnt production could contribute to
the maintenance of urothelial progenitors. Indeed, inhibition of
Wnt secretion led to reduced expression of proliferation markers
without major effects on the differentiation signature genes. In
bladder cancer, genes involved in Wnt signaling are rarely
mutated but epigenetic deregulation and deletion of sFRP1,
coding for a Wnt pathway antagonist, has been reported in 25%
of tumors36. Similarly, a role for Wnt has been proposed on the
basis of the cooperation of mutant β-catenin with Pten deletion or
HRas activation in mice37,38. These findings highlight the similar
dependencies of normal and tumor cells across species.
Mullenders et al. have recently reported that EGF was not
required for the long-term maintenance of their organoids,
indicating that there may exist different urothelial cell popula-
tions with specific growth dependencies. In addition, organoid
culture in the presence of FGFs resulted in pervasive branching
and tube extension, morphological features that are only excep-
tionally observed in our culture conditions23.
We show unequivocally that urothelial organoids undergo
differentiation as determined by the expression of urothelial
signature markers, as well as by global transcriptomic analysis.
Growth factor removal led to the downregulation of basal
signature genes, including epidermal skin transcripts, and the
upregulation of uroplakins and tight junction components. P
organoids display a default squamous-like differentiation
program while the D counterpart represents a late—but
incomplete— differentiation state as indicated by the hetero-
geneous expression of uroplakins, the lack of morphologically
distinguishable luminal umbrella cells, and the paucity/absence
of KRT20-expressing cells under the conditions examined. We
speculate that the nature of the organoid cell-of-origin, mul-
tinucleation, mechanical forces involved in bladder wall dis-
tension, and in vitro exposure to urine—among others—may
additionally contribute to the formation of umbrella cells and
the activation of its characteristic terminal differentiation
program23,39. Despite the lack of umbrella cells, the tran-
scriptomics analyses provide evidence of the activation of a
physiologically relevant gene expression program that results
in the formation of organoids displaying impermeability,
confirmed by functional assays using FITC-dextran. Interest-
ingly, RNA-Seq unveiled differential expression of transcripts
coding for members of the Claudin family in proliferative and
differentiation conditions. These findings suggest the con-
tribution of cells other than umbrella cells to the barrier
function, although our in vitro studies reported cannot be
directly compared with the in vivo situation. In addition, it is
conceivable that Claudins—and other tight junction proteins—
contribute to other processes beyond cell–cell adhesion6.
The organoid system described is validated by the response to
established regulators of urothelial differentiation such as PPARγ
and EGFR inhibitors. Previous studies using 2D cultures had
shown that TERT-immortalized urothelial cells lost the ability to
respond to PPARγ agonists40. By contrast, our organoids undergo
differentiation upon culture with PPARγ activators and EGFR
inhibitors in complete medium after several in vitro passages.
Organoids retained differentiated features in the absence of
complete medium components and upon inhibition of PPARγ
with an inverse agonist, suggesting either residual PPARγ activity
or the participation of additional signaling pathways. In this
regard, bulk organoid transcriptomics analysis pointed to a pre-
viously unknown role of Notch in normal urothelial differentia-
tion that was confirmed using scRNA-Seq and two different γ-
secretase inhibitors. The single-cell analyses revealed highest
levels of the Hes1 in cells with intermediate differentiation fea-
tures, suggesting transient pathway activation during differ-
entiation. These findings are consistent with genetic evidences
indicating that somatic mutations in genes coding for Notch
pathway components occur in urothelial tumors41–44 and
downregulation of NOTCH1 and DLL1 transcript levels in blad-
der cancer cells45. Notch activation can suppress bladder cancer
cell proliferation by direct upregulation of dual-specificity phos-
phatases; accordingly, ERK1 and ERK2 phosphorylation was
associated with NOTCH inactivation and tumor aggressiveness41.
The findings in human samples are supported by studies using
genetic mouse models: ubiquitous or urothelium-specific inacti-
vation of Nicastrin, a γ-secretase complex component, led to
BASQ-like tumors and this phenotype was suppressed by indu-
cible overexpression of Notch-IC41. In addition, urothelial dele-
tion of Presenilin-1/2 or Rbpj accelerated carcinogen-induced
squamous tumors with of epithelial-to-mesenchymal features44.
These results indicate that Notch is not only involved in
tumorigenesis but it also supports differentiation in the urothe-
lium. Inactivation of this pathway is co-opted during carcino-
genesis to promote the development of poorly differentiated,
aggressive, tumors.
Methods for the expansion of human urothelial tumors as
organoids have been reported recently22,23. This work shows that
the organoids largely reflect the genetic alterations present in the
original tumors and they display the phenotype of the major
bladder cancer subtypes. They also maintain substantial pheno-
typic stability while exhibiting plasticity upon in vivo expansion.
Furthermore, preliminary evidence indicates that organoids may
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predict in vivo drug responses. The most fundamental difference
of the culture conditions used in the study of Lee et al.22 and ours
refers to the use of fetal bovine serum. The growth medium used
in this study has not allowed the expansion of normal human
urothelium or bladder tumors from patients. Further work is
required to identify species- and tissue-specific growth require-
ments, considering the recent reports on human bladder cancer
organoids22,23.
We describe a single-cell transcriptomic analysis of the orga-
noids that not only substantiates the findings at the whole
population level but it also provides clues as to the molecular
mechanisms involved in urothelial differentiation and home-
ostasis. For example, cells in the Basal cluster are enriched for
expression of several collagen transcripts, suggesting
epithelial–mesenchymal features. Intermediate cells are enriched
in transcripts for several transcription factors not previously
known to be involved in urothelial differentiation, including
HOPX and FOXQ1. Interestingly, FOXQ1 is expressed at highest
levels in the bladder (https://gtexportal.org/home/); while rarely
altered in tumors, the highest frequency of FOXQ1 mutations
occurs in bladder cancer, with clustering in the vicinity of the
forkhead domain (https://www.intogen.org/search). By contrast,
Gata3, Foxa1, and Pparγ are not differentially expressed among
the clusters, pointing to the existence of differentiation regulatory
networks with distinct structures. We also identify cell surface
markers of these populations that will allow the isolation and
characterization of urothelial cell subsets with greater precision.
Among them is PSCA, the expression of which is influenced by
genetic polymorphisms associated with bladder cancer risk46,47.
The identification of a mouse urothelial stem cell population
able to form organoids with high efficiency, while maintaining
differentiation capacity, should facilitate the study of the mole-
cular pathophysiology of bladder diseases, including the interac-
tion of epithelial cells with pathogens. These tools will also allow
dissecting the molecular mechanisms through which oncogenes
and tumor suppressors contribute to bladder cancer.
Methods
Mice. C57BL/6 (Jackson Laboratories, 000664 RRID:IMSR_JAX:000664), Hsd:
Athymic Nude-Foxn1nu (Jackson Laboratories, 002019), 129-Gt.ROSA26 Sor-
CAG-EGFPLuo (Jackson Laboratories, 006053), and ROSA26 mT/mG mice (Jack-
son Laboratories, 007576) were housed in a specific pathogen-free environment
according to institutional guidelines. 129-Gt.ROSA26 Sor-CAG-EGFPLuo mice
were kindly provided by Maria A. Blasco (CNIO). Mice were sacrificed by CO2
inhalation. Urothelial bladder suspensions were produced from 7- to 12-week-old
mice both for the establishment of organoids and for fluorescence-activated cell
sorting (FACS) analyses. For xenograft transplantation, Hsd:Athymic Nude-
Foxn1nu mice were injected with 106 cells in 100 μL Matrigel under the flank or
5 × 104 cells in 50 μL Matrigel under the kidney capsule. All experiments were
performed in accordance with the guidelines for Ethical Conduct in the Care and
Use of Animals as stated in The International Guiding Principles for Biomedical
Research involving Animals, developed by the Council for International Organi-
zations of Medical Sciences (CIOMS), and approved by the institutional Ethics and
Animal Welfare Committee (Instituto de Salud Carlos III, Madrid, Spain).
Cell lines. ScaBER, RT112, VM-CUB-1, and RT4 urothelial bladder cancer cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich,
D5671), supplemented with 10% FBS (HyClone, Logan, UT, USA), 1% sodium
pyruvate (Life Technologies, 11360070), and 1% penicillin/streptomycin (Gibco,
15140122) (basic DMEM). VM-CUB-1 cells were used as a positive control for the
xenograft experiments. LWnt3a- producing cells transfected with the Wnt3A
cDNA (a kind gift from Dr. E. Batlle) were used to produce Wnt3A conditioned
medium48. RSPO1 was supplemented as the conditioned medium of Expi293 (Life
Technologies, A14527) cells transfected with a pOPINE-G-RSPO1-His6 plasmid (a
kind gift of Dr. E. Batlle) using the ExpiFectamine™ 293 Transfection Kit (Ther-
moFisher, A14525). The activity of both conditioned media was confirmed by
testing their effect on Axin2 mRNA expression in HeLa cells using RT–qPCR.
Murine macrophage RAW 264.7 cells (a kind gift from Dr. M. Soengas) were
maintained in basic DMEM and used to confirm the pharmacological modulation
of PPARγ activity. Cells were seeded at 70% confluence in basic DMEM supple-
mented with oxLDL (15 μg/mL) alone or with either Roziglitazone (10 μM) or
T0070907 (2 μM). After 2 h, cells were cultured with basic DMEM supplemented
with oxLDL (15 μg/mL). After 48 h, RNA was extracted. All cells were allowed to
settle in a humidified incubator at 37 °C, 5% CO2. All cell lines used were
Mycoplasma-free.
Establishment of mouse organoids. Mice were sacrificed and the bladder was
accessed and turned inside-out leaving the urothelial surface exposed. The uro-
thelium was enzymatically digested with collagenase P (0.5 μg/mL) (Roche,
11215809103) in Hank’s Balanced Salt Solution (HBSS) (Life Technologies,
14025050) in a thermoblock with gentle shaking at 37 °C for 20 min. Collagenase P
was inactivated with 2 mM EDTA and 50% FBS. The cell suspension was collected
and the remaining urothelium was scraped. After filtration through a 70-μm
strainer and centrifugation at 1200 r.p.m. for 5 min at 4 °C, the pellet was washed
2× with washing medium [Advanced DMEM F12 medium (Gibco, 12634010)+ 1×
HEPES (Gibco, 15630080)+ 1× Glutamax (Gibco, 35050061)] and cells were
embedded in growth factor-reduced and phenol red-free Matrigel (Corning,
356231). Matrigel-cell suspensions (20 μL drops) were plated onto six-well plates,
allowed to settle in a humidified incubator at 37 °C/5% CO2, and overlaid with
2 mL complete medium (see below). Medium was replaced every 2–3 days. Cul-
tures were usually expanded at a 1:4–1:6 ratio every 7–10 days. After Matrigel
removal with Cell Recovery Solution (Corning, 354253) on ice, the cell suspension
was washed with phosphate-buffered saline (PBS), then with washing medium, and
centrifuged at 1200 r.p.m. for 5 min at 4 °C. Then, organoids were chemically
digested with Dispase II solution (10 mg/mL) (Gibco, 17105041) for 15–20 min in a
rotating wheel at room temperature. The reaction was neutralized with 2 mM
EDTA and single cells were obtained by mechanical disruption with a syringe with
a 21G needle for at least strokes. After two washes with washing medium, the pellet
was embedded in fresh ice-cold Matrigel, seeded on six-well plates, and covered
with medium as described. Unless otherwise specified, organoids were maintained
in culture with complete medium [Advanced DMEM/F12, 1× penicillin/strepto-
mycin, 1× HEPES, 1× GlutaMAX, 50% WNT3A conditioned medium, 5% human
RSPO1 conditioned medium, 1× N2 (Gibco, 17502048), 1× B27 (Gibco, 12587010),
50 ng/mL human recombinant EGF (Invitrogen, PHG0311L), 1 mM N-acet-
ylcysteine (Sigma-Aldrich, 616-91-1), 50 μg/mL human Noggin (Peprotech, 120-
10C) and 1 μM LY2157299 (AxonChem, 700874-72-2)]. The ROCK inhibitor Y-
27632 (10 μM) (Sigma-Aldrich, 129830-38-2) was added during the first 3 days of
culture. For differentiation experiments, organoids were cultured for the first 7 days
in complete medium, reseeded (without disaggregation) in fresh Matrigel, and
cultured either with complete or differentiation medium (lacking WNT3A and
RSPO1 conditioned medium, EGF, LY2157299, and Noggin) for the following
7 days. PPARγ modulators were added to the medium (complete or differentiated)
as indicated in the text, at the following concentrations: Rosiglitazone (1 μM)
(Sigma-Aldrich, 122320-73-4), T0070907 (10 μM) (Sigma-Aldrich, 313516-66-4).
The EGFR inhibitor Erlotinib was used at 0.5 μM (Sigma-Aldrich, CDS022564).
The γ-secretase inhibitors DAPT (5 μM) (Sigma-Aldrich, 208255-80-5) or DBZ
(2.5uM) (Tocris, 4489), porcupine inhibitor IWP-2 (5 μM) (Merk, 681671), and
Wnt agonist CHIR99021 (2.5 μM) (Tocris, 4423) were added to P organoids on day
7 and organoids were allowed to grow in differentiation medium until day 14.
Microphotographs were taken using an inverted microscope (Olympus CK-30). In
order to cryopreserve organoids, 7-day cultures were washed once in PBS, Cell
Recovery Solution was added, and cells were collected and placed on ice for 30 min.
After washing once with PBS, then with washing medium, and centrifugation at
1200 r.p.m. 4 °C for 5 min, organoids were resuspended in freezing medium [10%
DMSO (Sigma-Aldrich, D2650) in Advanced DMEM/F12 supplemented with
10 μM Y-27632] at a density equivalent to three confluent drops/500μL. Cryovials
were stored at −80 °C. For thawing, vials were placed in a 37 °C water bath and the
contents washed twice with Advanced DMEM/F12 before reseeding in Matrigel at
the required density.
In experiments analyzing FACS-sorted populations, cell viability of the different
populations was assessed and found to be comparable.
All experiments reported were performed without cell sorting based on EpCAM
expression, using low-passage cultures (<10), unless stated otherwise.
For all major experiments, at least two—and generally three—independent
biological replicates—in addition to technical replicates—were performed.
Flow cytometry analysis. Urothelial cell suspensions obtained as previously
described were incubated with blocking buffer (1% bovine serum albumin (BSA)/
3 mM EDTA in PBS) for 15 min at room temperature. After washing twice with
PBS, cells were incubated with FITC-labeled anti-mouse EpCAM (BioLegend,
118207), APC-labeled anti-mouse EpCAM (BioLegend, 118213), FITC-labeled
WGA (Vector Laboratories, FL-1021), PE-labeled anti-mouse/human CD49f (BD
Biosciences, 555736), APC-labeled anti-mouse CD45 (BD Biosciences, 559864, PE-
labeled anti-mouse CD31 (BD Biosciences, 555027), PE-labeled anti-mouse
CD140a (Labclinics, 16-1401-82), PE-labeled anti-mouse Ter119 (BioLegend,
116208), and/or APC-labeled anti-mouse/human CD44 (BioLegend, 103011)
antibodies in FACS buffer (0.1% BSA/3 mM EDTA in PBS) for 30 min at 4 °C.
After washing twice with PBS, cells were resuspended in FACS buffer and stained
with DAPI (Sigma-Aldrich, D9542). In all the experiments a control sample lacking
primary antibody and a Fluorescence Minus One (FMO) control were used. In the
experiments using isolated urothelial cells, EpCAM+ single cells were sorted by
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FACS and dead cells were excluded from subsequent analyses. In the experiments
with organoids, samples were disaggregated as previously described and single-cell
suspensions were incubated with PE-labeled anti-mouse/human CD49f antibody.
In the case of D < 70 μm and D > 70 μm, organoids cultured for 7 days in complete
medium were filtered using a 70 μm filter and the fall through and the retained
organoids were reseeded in Matrigel and cultured in differentiation medium. All
samples were analyzed using a FACS Influx or AriaII (BD Biosciences) flow cyt-
ometer and at least 10,000 events were acquired. Analyses were performed using
FlowJo version 10.2 flow cytometer analysis software.
Clonality experiments. FACS-sorted freshly isolated urothelial cells were
embedded in 5 μL of Matrigel in a 96-well format at 1, 10, or 100 cells/well for the
clonal growth experiments. For the monoclonality experiment, organoids derived
from mice of the 129-Gt.ROSA26 Sor-CAG-GFPLuc and ROSA26 mT/mG;Ubc-
CreERT2 strains were separately established; after dissociation to single-cell sus-
pensions they were mixed at a 1:1 ratio and allowed to grow as organoids in 20 μL
of Matrigel/drop in 48-well plates at 1000 cells/well. Organoids containing cells of
the corresponding fluorescent color (EGFP, Tomato, and chimeras) were counted.
Cell cycle re-entry experiments. Urothelial cell suspensions were seeded in
complete medium for 7 days. Afterwards, organoids were resuspended in Matrigel
and cultured for the following 7 days either in complete medium, differentiation
medium, or in differentiation medium supplemented with Rosiglitazone (1 μM)
and Erlotinib (0.5 μM). On day 14, the medium was replaced with either complete
or differentiation medium and cultures were allowed to grow until day 21.
Organoid quantification. For the leave-one-out experiments, images were
acquired with ×40 resolution with CCD-microscope using a brightfield filter. Three
pictures in the Z-axis were taken in order to collect the majority of the organoids.
Then, a Z-stack was done using ImageJ software. For immunofluorescence and
growth assays, quantification was performed with tailored routines programmed in
Definiens XD v2.5 software. Data on organoid features (layer thickness, lumen, and
diameter) were derived from the signal distribution upon Hoechst staining.
Organoid growth and time-lapse videos were acquired using a DMI6000B
brightfield microscope from Leica Microsystems with an HC PL APO ×10 0.4 NA
dry objective. Cells were maintained in a temperature-controlled (37 °C), humi-
dified environment in the presence of 5% CO2 during imaging.
Barrier function assays. A derivative of FRAP-derived strategy was used whereby
the influx of Fluorescein isothiocyanate–dextran (average mol wt 3000–5000)
(Sigma-Aldrich, 60842-46-8) into the organoid is measured after bleaching the
original fluorescence. Organoids were cultured in μ-slide eight-well Ibidi plates
(Ibidi, 80826). In the pre-bleaching step, the original signal was registered. After
bleaching by pointing the laser into the lumen for 20 s (488 nm wavelength at
maximum power), the signal decayed and a new register was established. In the
recovery phase, the entrance of FITC-dextran into the lumen was measured. The
recovery period spanned for a total of 14 h, with images acquired every 30 min. The
assay was performed using a Leica TCS-SP5 (AOBS) Leica Microsystem laser
scanning confocal microscope with a ×40 immersion oil objective (HCX PLAPO
1.2 NA). The normalized intensity of luminal FITC-dextran was calculated by
dividing the measurements corresponding to the region of interest in the lumen by
the background in the Matrigel.
Western blotting. Organoids were pelleted after removing Matrigel with Cell
Recovery Solution and whole cell extracts were prepared using RIPA buffer [0.05 M
Tris-HCl pH 7.5, 0.1% SDS, 0.15M NaCl, 1% Triton X-100 (Sigma-Aldrich) and
1% sodium deoxycholate] containing protease and phosphatase inhibitors (leu-
peptin, 10 μg/mL; aprotinin, 10 μg/mL; PMSF, 1 mM; orthovanadate, 1 mM; NaF,
1 mM; all from Sigma-Aldrich). Cell lysates were fractionated by SDS-PAGE,
transferred to PVDF membranes, and incubated with the following primary
antibodies: mouse monoclonal anti-UPK3a (Santa Cruz, sc-166808), mouse
monoclonal anti-UPK1b (a kind gift from Dr. A. García-España), goat polyclonal
anti-Lamin (Santa Cruz, sc-6216), rabbit monoclonal anti-HES1 (a kind gift from
Dr T. Sudo), mouse monoclonal anti-TP63 (Abcam, ab735). Enhanced chemilu-
miniscence was used; films were exposed to ensure that bands were not saturated.
Immunofluorescence and immunohistochemistry. Matrigel drops containing
organoids were collected 7 days after seeding, fixed in 10% formalin, and embedded
in paraffin. Mouse bladders (C57BL/6) were embedded in OCT or formalin-fixed
and paraffin-embedded. Sections (3 μm) were obtained for immunofluorescence
and immunohistochemistry analyses. After deparaffinization and rehydration,
antigen retrieval was performed by boiling in citrate buffer pH 6 for 10 min. For IF,
sections were incubated with 3% BSA/0.1% Triton in PBS for 45 min at room
temperature and incubated with primary antibodies overnight at 4 °C. After
washing with 0.1% Triton/PBS, the appropriate fluorochrome-conjugated sec-
ondary antibodies (Alexa Fluor 488-labeled goat anti-mouse Ig (A-11001), Alexa
Fluor 555-labeled goat anti-rabbit Ig (A-21428), Alexa Fluor 488-labeled goat anti-
chicken Ig (A-11039), and Alexa Fluor 680-labeled goat anti-rabbit Ig (A-27042);
Life Technologies) were added for 45 min, sections were washed, and nuclei were
counterstained with DAPI. After washing with PBS, sections were mounted with
Prolong Gold Antifade Reagent (Life Technologies, P36930). Images were acquired
using a confocal microscope (Leica, SP5) with a ×40 immersion oil lens and a zoom
of 1–2.5. For immunohistochemistry, endogenous peroxidase was blocked with 3%
H2O2 in PBS for 30 min, sections were incubated with 3% BSA/0.1% Triton in PBS
for 45 min at room temperature, and with primary antibody overnight at 4 °C.
After washing with 0.1% Triton/PBS, sections were incubated with the appropriate
secondary antibodies (Envision kit for mouse K4001 or rabbit K4003 Ig, Dako) for
45 min, washed, and reactions were developed with DAB (Dako, K3468). Sections
were lightly counterstained with hematoxylin, dehydrated, and mounted. All
shown images are representative of >10 random fields.
The following reagents were used: FITC-labeled WGA (Vectorlabs, FL-1021),
PE-labeled anti-mouse/human CD44 (BioLegend, 103023), PE-labeled anti-mouse/
human CD49f (BD Biosciences, 555736), mouse monoclonal anti-Claudin4 (Santa
Cruz, sc-376643), rat monoclonal anti-Zo-1 (Santa Cruz, sc-33725), rabbit
monoclonal anti-PPARγ (Cell Signalling, 2435T), rabbit polyclonal anti-Ki67
(Novocastra, NCL-Ki67p), rabbit monoclonal anti-FOXA1 (Abcam, ab173287),
mouse monoclonal anti-E-Cadherin (BD Biosciences, 610181), rabbit monoclonal
anti-Cleaved-caspase-3 (Cell Signalling, 9579), rabbit polyclonal anti-KRT5
(BioLegend, 905501), rabbit polyclonal anti-KRT14 (BioLegend, 905301), anti-
TP53, mouse monoclonal anti-UPK3a (Santa Cruz, sc-166808), mouse monoclonal
anti-UPK1b (kind gift from Dr. A. García-España), rabbit monoclonal anti-ITGA6/
CD49f (Abcam, ab181551), and rat monoclonal anti-HES1 (395A/A7, CNIO
Monoclonal Antibody Core Unit). Antibody concentrations are provided in the
Nature Protocol Exchange article49 and Reporting summary.
Real-Time quantitative PCR. Total RNA was extracted from organoids using the
TRI Reagent® (Sigma-Aldrich, T9424) followed by the PureLinkTM RNA Mini Kit
(Life Technologies, 12183020), according to the manufacturer’s instructions. For
cells grown in 2D culture, RNA was extracted using ReliaPrepTM RNA Cell
Miniprep System Kit (Promega, TM370). Samples were treated with DNase before
reverse transcription (Life Technologies, AM1906). cDNA was generated from 200
to 1000 ng of RNA using random hexamers and reverse transcriptase using the
TaqMan® Reverse Transcription Reagents (Life Technologies, N8080234). Reaction
mixes lacking RT were used to ensure the absence of genomic DNA contamination.
PCR amplification and analyses were conducted using the 7900HT Real-Time PCR
System (Applied Biosystems, Life Technologies) using GoTaq® qPCR Master Mix
(Promega, TM318). Gene-specific expression was normalized to Hprt (organoid
cultures), β-actin (RAW 264.7 cells), and GAPDH (HeLa cells) using the ΔΔCt
method. For RT–qPCR, primer pairs were designed to achieve inter-exon products
of 200–250 bp. Primer sequences are provided in Supplementary Table 1.
Bulk RNA-sequencing analysis. RNA quality was assayed by laboratory chip
technology on an Agilent 2100 Bioanalyzer. PolyA+ RNA was isolated from total
RNA (1 μg, RIN > 9), randomly fragmented, converted to double stranded cDNA,
and processed through subsequent enzymatic treatments of end-repair, dA-tailing
and ligation to adapters according to Illumina’s TruSeq RNA Sample Preparation
v.2 Protocol. The adaptor-ligated library was completed by limited-cycle PCR with
Illumina PE primers (8 cycles). The resulting purified cDNA library was applied to
an Illumina flow cell for cluster generation (TruSeq cluster generation kit v.5) and
sequenced on a Genome Analyzer IIx with SBS TruSeq v.5 reagents, according to
the manufacturer’s protocols. The sample sequencing was paired-end. Three paired
samples of organoids cultured in proliferative and differentiation conditions were
analyzed. The Nextpresso version 1.9.1 analysis pipeline (Bioinformatics Unit,
CNIO, Madrid) was used to process the data with the version MGSCv376/mm8 of
the mouse genome50. Promoter motif analysis of differentially expressed genes was
performed using ISMARA version 1.2.1.
Principal component analysis. The Pearson correlation was calculated from the
expression values (expressed as fragments per kilobase of transcript per million
mapped reads) of each gene for each sample by using the “cor” command in R
(https://www.r-project.org/). Principal component analysis was performed using
the “prcomp” command in R, from the correlation value of each sample.
Gene Set Enrichment Analysis. The list of genes was ranked by the “t-stat”
statistical value from the cuffdiff output file. The list of pre-ranked genes was then
analyzed with GSEA for Gene Ontology (GO) database. Significantly enriched GO
terms were identified using a false discovery rate q value of less than 0.25. The
analyses were carried out as defined in http://www.broadinstitute.org/gsea/doc/
GSEAUserGuideFrame.html?Interpreting_GSEA.
Droplet based single-cell mRNA sequencing. Organoids were enzymatically
dissociated and cells were suspended in PBS with 0.04% BSA (Ambion AM2616).
Cells (10,000 per condition, cell viability >70%) were loaded onto a 10x Chromium
Single Cell Controller chip B (10x Genomics) as described in the manufacturer’s
protocol (Chromium Single Cell 3ʹ GEM, Library & Gel Bead Kit v3, PN-1000075).
Generation of gel beads in emulsion (GEMs), barcoding, GEM-RT clean up, cDNA
amplification, and library construction were performed following the
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manufacturer’s recommendations. Libraries were loaded at a concentration of
1.8 pM and sequenced in an asymmetrical pair-end format, with 28 bases for read 1
and 56 for read 2 in a NextSeq500 instrument (Illumina). Sequencing depth was 58
and 53 million paired reads for proliferative and differentiated organoids,
respectively.
Single-cell RNAseq data computational analysis. Reads were locally processed
with Bcltofastq (bcl2fastq 2.19.0; Illumina). Cell Ranger version 3.0.2 software (10x
Genomics) pipeline was then used to demultiplex and align reads to the GRCm38/
mm10 transcriptome. FastQC software was used to check sequencing read quality.
Cell Ranger count generated the matrices used in the next analysis step.
Cell Ranger matrix data (barcodes, features, and count matrix) were loaded
onto the Seurat R package (version 3.0.0.9000). In order to identify and exclude
low-quality cells from downstream analyses pre-processing was performed for both
datasets. The distribution of UMIs (Unique Molecular Identifiers), genes, and the
percentage of mitochondrial-encoded genes across cells were visualized using the
ggplot2 R package. Cells with >800 genes detected were kept. Since a high
percentage of mitochondrial genes is considered a characteristic of low-quality
cells51, cells expressing >12% of mitochondrial genes were excluded from
downstream analysis (Supplementary Fig. 9). After the filtering steps outlined
above, 6826 cells with a median gene count of 1151.5 were retained for downstream
analysis of the proliferative organoids and 4896 cells with a median gene count of
1346.5 were retained for downstream analysis of the differentiated organoids.
Normalization of filtered cells was performed by dividing gene counts for each
cell by the total number of counts for that cell multiplied by a scale factor (10,000-
default parameter) and then natural log-transformed.
To identify genes exhibiting high variability across cells in each dataset, and use
those heterogeneous features in downstream analysis, we used “vst” method
implemented in Seurat v3 FindVariableFeatures function52. This method performs
feature selection by computing the mean and variance of each gene using
unnormalized data and applying log 10 transformation to both and then fitting a
line to the relationship of log(variance) and log(mean) using local polynomial
regression (loess). Standardized feature values are obtained with the observed mean
and the expected variance, given by the fitted line. Feature variance is then
calculated on the standardized values after clipping to a maximum value (default
parameter: square root of the number of cells). This variance is used to rank the
features for each dataset. A subset of 2000 genes (Supplementary Fig. 7b,
Supplementary Data 2) exhibiting high cell-to-cell variation was selected for
downstream analysis. Lastly, genes were scaled and centered in each dataset by z-
normalization to standardize the dynamic range across genes. This was done to
ensure subsequent downstream analysis was not biased towards highly
expressed genes.
Linear dimensional reduction was performed on the scaled data using principal
component analysis (PCA). Elbow plots and JackStraw permutations test were
applied to determine the dimensionality of each dataset as significant principal
components (p value cut-off of less than 0.05) (25 PCs for proliferative and 21 PCs
for differentiated organoids).
The minimal number of clusters was estimated by determining the robustness
of the consensus matrix using SC3 R package53. The identification of biologically
relevant communities was performed by means of a graph-based clustering in
Seurat through the construction of a KNN graph and posterior cell clusterization
using the Louvain algorithm (resolution 0.2). Cell clusters were visualized using
uniform manifold approximation and projection (UMAP)54 plots with previously
selected significant components as an input.
Cluster gene markers were detected with Seurat R package using a Wilcoxon
rank sum test between each cluster and the rest of cells in the dataset and p value
adjustment was performed using Bonferroni correction based on the total number
of genes in the dataset.
Both organoid datasets were integrated into a shared space through the
identification of common shared features termed anchors between cells across P
and D organoids52. Both datasets were pre-processed and normalized separately as
described above. Dimensional reduction was performed by means of canonical
correlation analysis (CCA)55. We defined the dimensionality of the integrated
dataset by using 25 canonical vectors CCV (maximum number of significant
principal components chosen in individual analysis) that project the two datasets
into a correlated low dimensional space. After dimensional reduction, we identified
the K nearest neighbors (KNNs) for each cell within both datasets, using the L2
normalized CCV. Lastly, we identified the “anchors” as pairwise correspondences
by mutual nearest neighbors (MNN). These anchors were filtered and scored to
reduce the effect of incorrect identification and weighted in a matrix that defines
the strength of association of each cell and each anchor. Batch correction was then
performed by matching MNN as described by Haghverdi et al.56. These steps were
implemented in the FindIntegrationAnchors and IntegrateData Seurat functions.
Downstream analysis on the integrated dataset was performed as it was done for
individual analysis (Clustering (resolution 0.17), Cluster markers, and differential
expression analysis).
Additional resources. Claudin expression data were extracted from the Human
Protein Atlas (www.proteinatlas.org). GenePattern was used to compute all heat-
maps here presented. IDraw was used to generate the panels and figures.
Quantification and statistical analyses. All quantitative data are presented as
mean ± s.e.m. from ≥2 experiments or samples per data point (n is mentioned in
each figure legend). Non-parametric Mann–Whitney U test (two-tailed) was used
to assess significance levels and ANOVA was used to compare more than two
groups. Statistical analysis was performed using GraphPad Prism version 6 soft-
ware. For further statistical details, refer to each figure legend. For in vitro
experiments, sample size required was not determined a priori. The experiments
were not randomized.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the article and its supplementary information. The bulk RNAseq data generated in this
study have been deposited in the GEO database under accession code: GSE109566. The
single-cell RNA-Seq data have been deposited in the GEO database under accession code:
GSE131909. Materials, other data, and Excel files with significantly differentially
regulated genes and pathways are available upon reasonable request to the authors. A
step-by-step protocol describing the establishment, maintenance, and differentiation of
organoids can be found at Nature Protocol Exchange with DOI 10.21203/rs.2.12413/v149.
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